MARKET WIREStocktwits • 15h ago
EMBC: Embecta Corp Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
Why EMBC Stock dropped -4.73% Today — RQD Quant Desk Flash
$6.25 -4.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.18
Embecta Corp. (EMBC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $354.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EMBC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Embecta Corp. (NASDAQ: EMBC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $6.25 (-4.73% 1D, market cap $354.1M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, EMBC ranks #96 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EMBC compare to MOBI and CLPT in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), EMBC carries a Roarable C+ (68/100 RQD), trailing P/E of 3.9x, gross margin of 62.6%, and ROIC of 35.5%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.0M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EMBC?
▼
Per EMBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001872789), Embecta Corp. generated $1.08B in revenue (-3.8% YoY), $95.4M in net income, and $182.4M in free cash flow against $1.06B in total assets and $1.35B in total debt. Key quantitative strengths: Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.19 (-1.04%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 16.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE+4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EMBC)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (68/100 Composite)
🔍 WHY EMBC SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 16.9% FCF Margin ($182.4M FCF) & 62.6% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$6.20+3.5% Next Q
60
Q2 (-2Q)Grade C+$6.42+2% Next Q
63
Q3 (-1Q)Grade C+$6.55-4.6% Next Q
65
CurrentGrade C+$6.25+1.8% Hist 90D α
68
Trajectory: C (60) → C+ (68)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the EMBC Bull Thesis Could Fail
Even with a 68/100 (C+) score, EMBC faces multiple-compression risk if 3.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 60.1% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.79) or 200D SMA ($6.38) invalidates the momentum regime and cuts Target Base ($6.53) toward Bear Floor ($5.09).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EMBC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EMBC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EMBC Stock dropped -4.73% Today — RQD Quant Desk Flash
Embecta Corp. (EMBC) dropped -4.73% to $6.25, trading at 29% of its 52-week range ($2.77 – $14.91). Solid 63% profit margin (36% return on capital), mixed timing at 4x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 29% of its 52-week range ($2.77 – $14.91) with RSI-14 at 51.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.6% around $6.25 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 62.6% gross margin and $182.4M annual free cash flow.
Live EMBC Headlines & Catalysts
RISK WATCHYahoo Finance • 18h ago
What Embecta Bears Saw Before A 55% DropYahoo Finance report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 21h ago
Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC) and Airsculpt Technologies (AIRS)The Globe and Mail report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe National Law Review • 1d ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Embecta Corp. (EMBC) And Encourages Stockholders to ConnectThe National Law Review report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Why Is Embecta (NASDAQ:EMBC) Up 6.86% on Light Volume With No Catalyst Found?kalkine.ca report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Did Embecta's 52% Fall Catch You Out? What Investors MissedSimply Wall St report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Embecta Q3 Earnings Call HighlightsTradingView report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
How Embecta Corp. (EMBC) Affects Rotational Strategy TimingStock Traders Daily report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (EMBC Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EMBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.43%▲ ASCENDING CHANNEL
2026-11-03O $6.56H $6.56L $6.25C $6.25VOL 831.1K
RES: $7.14SUP: $3.73SMA50: $5.79SMA200: $6.38
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EMBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-15.0%/yr Implied 5Y Growth
vs. -3.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EMBC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EMBC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EMBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EMBC)
Health Care Rank #96 of 1016
⚔️ MOBI vs EMBC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EMBC vs. MOBI, CLPT, OFIX, SI)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Embecta Corp. (EMBC) ranks #96 by composite RQD confidence (68/100, grade C+) and #494 by equity capitalization ($354.1M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EMBC
ACTIVE
Embecta Corp. | C+ | 68/100 | 3.9x | 62.6% | 35.5% | -4.73% | $354.1M | Benchmark Subject |
| MOBI Mobia Medical Inc. | D | 50/100 | — | — | — | -6.12% | $352.2M | /mobi-vs-embc → |
| CLPT ClearPoint Neuro Inc. | E | 19/100 | — | 61.4% | -35.0% | -0.19% | $342.0M | /clpt-vs-embc → |
| OFIX Orthofix Medical Inc. | D- | 42/100 | — | 68.8% | -12.2% | -11.43% | $369.4M | /ofix-vs-embc → |
| SI Shoulder Innovations Inc. | D | 44/100 | — | 76.5% | -16.1% | -6.41% | $398.3M | /si-vs-embc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001872789In its most recent audited fiscal period (FY2025, filed 2025-09-30), Embecta Corp. (EMBC) reported GAAP revenue of $1.08B (-3.8% vs. FY2024 revenue of $1.12B , and -3.6% cumulative change since FY2023) , GAAP net income of $95.4M, operating cash flow of $191.7M, and free cash flow of $182.4M (+816.6% YoY). On the balance sheet, EMBC closed FY2025 with $1.06B in total assets against $1.35B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $1.08B | $95.4M | $191.7M | $182.4M | $1.06B | $1.35B |
| FY2024 (FY) | 2024-09-30 | $1.12B | $78.3M | $35.7M | $19.9M | $1.15B | $1.53B |
| FY2023 (FY) | 2023-09-30 | $1.12B | $70.4M | $67.7M | $67.7M | — | — |
3. EMBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Embecta Corp. (NASDAQ: EMBC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $6.25 (-4.73% 1D, market cap $354.1M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, EMBC ranks #96 in composite RQD confidence.
How does EMBC compare to MOBI and CLPT in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), EMBC carries a Roarable C+ (68/100 RQD), trailing P/E of 3.9x, gross margin of 62.6%, and ROIC of 35.5%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.0M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EMBC?
Per EMBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001872789), Embecta Corp. generated $1.08B in revenue (-3.8% YoY), $95.4M in net income, and $182.4M in free cash flow against $1.06B in total assets and $1.35B in total debt. Key quantitative strengths: Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EMBC trading relative to its 50-day, 200-day, and 52-week technical levels?
EMBC last traded at $6.25 (-4.73% on volume of 831,126 shares), positioning the stock +7.94% above its 50-day simple moving average ($5.79) and -2.04% below its 200-day simple moving average ($6.38). Across its 52-week range of $2.77 to $14.91, EMBC sits at the 28.7% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($5.65 to $6.85).
EMBC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is EMBC stock moving today?
Why EMBC Stock dropped -4.73% Today — RQD Quant Desk Flash. Solid 63% profit margin (36% return on capital), mixed timing at 4x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 68/100 (C+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
EMBC — Embecta Corp.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:32Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, EMBC scores 74 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are:
- Fundamental Cash Engine: 19 / 20. Per the RQD rating, this pillar reflects an ROIC of 35.5% alongside an FCF yield of 0%. The strong return on invested capital is the primary upside driver in this pillar, while the zero FCF yield is a valuation tradeoff: the reported free cash flow is not being returned to shareholders at the current market price.
- Whale 13F Flow: 11 / 20. Per the RQD rating, this pillar measures institutional accumulation and options positioning. The modest score suggests institutional flow is a weaker supporting factor than the fundamentals. Holder data in the source is not available, so the underlying positioning cannot be examined further here.
- Insider Conviction: 17 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is a relatively strong score, though the underlying trade detail is not available in the source data.
- Macro Regime Fit: 12 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves; the score indicates moderate rather than favorable macro alignment.
- Forensic Balance Sheet: 15 / 20. Per the RQD rating, this pillar reflects an Altman Z of 2.5, a Piotroski F of 7/9, and a Debt/Equity of 0.5. These support solvency and fundamental quality, but the reported debt level is a key consideration for a prospective investor.
Taken together, the rating points to strong cash-generation economics and reasonable forensic health, offset by weaker institutional flow and macro fit. For a prospective investor evaluating the stock today, the central question is whether the high ROIC and low trailing valuation outweigh the leverage and the absence of free-cash-flow yield.
Snapshot
Business
Embecta Corp. (EMBC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the company profile, its market capitalization is $0.4B. Per the market data, its gross margin is 62.6%, operating margin 22.4%, and net margin 8.8%. Product, customer, and revenue-model detail is not available in source data.
Recent Catalysts & News Wire Analysis
The news wire contains six items dated within roughly the prior 15 hours of the data timestamp. Per the news feed, the items are labeled as follows:
- Risk Watch (RED): "What Embecta Bears Saw Before A 55% Drop" (Yahoo Finance) and "Did Embecta's 52% Fall Catch You Out? What Investors Missed" (Simply Wall St). Both reference large declines in the stock, but the underlying causes are not available in source data.
- Market Wire (YELLOW): A Stocktwits general overview; an analyst-insights piece from The Globe and Mail naming EMBC alongside AIRS; a law-firm notice from The National Law Review stating that Bronstein, Gewirtz & Grossman, LLC is investigating Embecta Corp. (EMBC) and encouraging stockholders to connect; and a kalkine.ca item noting a 6.86% move on light volume with no catalyst found.
Per the news feed, the investigation notice is the most specific item; its substance and any allegations are not available in source data. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Open Questions
- What drove the reported 52–55% declines referenced in the news wire, and are they tied to the investigation notice?
- What is the nature of the investigation referenced by the law-firm notice, and what allegations, if any, are involved?
- Why is the FCF yield 0% when reported FY 2025 free cash flow is $182.4M, and how does that reconcile with the market capitalization?
- What is the composition of the $1352.9M debt, including maturities and refinancing exposure?
- What EPS values were reported for the financial periods, given that the source lists them as N/A?
EMBC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Embecta Corp. (EMBC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 15h ago
EMBC: Embecta Corp Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 18h ago
What Embecta Bears Saw Before A 55% Drop Yahoo Finance report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 21h ago
Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC) and Airsculpt Technologies (AIRS) The Globe and Mail report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The National Law Review • 1d ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Embecta Corp. (EMBC) And Encourages Stockholders to Connect The National Law Review report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Why Is Embecta (NASDAQ:EMBC) Up 6.86% on Light Volume With No Catalyst Found? kalkine.ca report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Did Embecta's 52% Fall Catch You Out? What Investors Missed Simply Wall St report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Embecta Q3 Earnings Call Highlights TradingView report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
How Embecta Corp. (EMBC) Affects Rotational Strategy Timing Stock Traders Daily report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EMBC Bull vs. Bear Conversation Board — What's Your Call at $6.25?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EMBC 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $7.74 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is EMBC (B • RQD 74/100) a Buy at $6.56?
Welcome to the EMBC (Embecta Corp.) Roar Pit. Current RQD Composite is 74/100 (Roarable Buy — Good Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (35.5% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.51 (-16.0%)
Spot @ $6.56 Pump the brakes on EMBC — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on EMBC, but look at what you are paying: 3.9x trailing P/E with 62.6% gross margins. Unless Embecta Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $7.81 (+19.1%)
Spot @ $6.56 EMBC cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on EMBC, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $6.56 (52-wk range $2.77 - $14.91), any beat on forward guidance forces shorts and underweight funds to chase.